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Abstract
Macrophages are the primary cell type infected with HIV in the central nervous system, and infection of these cells is a major
component in the development of neuropathogenesis and HIV-associated neurocognitive disorders. Within the brains of
drug abusers, macrophages are exposed to increased levels of dopamine, a neurotransmitter that mediates the addictive
and reinforcing effects of drugs of abuse such as cocaine and methamphetamine. In this study we examined the effects of
dopamine on HIV entry into primary human macrophages. Exposure to dopamine during infection increased the entry of R5
tropic HIV into macrophages, irrespective of the concentration of the viral inoculum. The entry pathway affected was CCR5
dependent, as antagonizing CCR5 with the small molecule inhibitor TAK779 completely blocked entry. The effect was dose-
dependent and had a steep threshold, only occurring above 108 M dopamine. The dopamine-mediated increase in entry
required dopamine receptor activation, as it was abrogated by the pan-dopamine receptor antagonist flupenthixol, and
could be mediated through both subtypes of dopamine receptors. These findings indicate that the effects of dopamine on
macrophages may have a significant impact on HIV pathogenesis. They also suggest that drug-induced increases in CNS
dopamine may be a common mechanism by which drugs of abuse with distinct modes of action exacerbate
neuroinflammation and contribute to HIV-associated neurocognitive disorders in infected drug abusers.
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Introduction
Human Immunodeficiency Virus type 1 (HIV) enters the
central nervous system (CNS) within 8 days of initial infection [1]
and leads to the development of HIV-associated neurological
disorders (HAND) in 40–70% of individuals [2–6]. Macrophages
and other cells of the monocytic lineage are the primary targets for
HIV infection in the CNS [7–10], although HIV also infects
astrocytes [8,11,12]. Macrophages are critical to HIV mediated
neuropathogenesis [13–16] and may serve as viral reservoirs
within the CNS [17,18]. Macrophages also release inflammatory
mediators and neurotoxic viral and host proteins, contributing to
chronic neuroinflammation and neurotoxicity [16,19,20]. Thus,
infection of CNS macrophages is central to HIV-associated
neuroinflammation and neurocognitive dysfunction.
Macrophages in the CNS are exposed to dopamine, a
catecholamine neurotransmitter that is increased by the use of
illicit drugs such as cocaine and methamphetamine [21,22], as well
as by legal therapeutics such as Ritalin and some antidepressants
[23,24]. Studies in SIV-infected rhesus macaques show that
increases in extracellular dopamine correlate with increased CNS
viral loads [25,26]. HIV-infected individuals show exacerbated
neuropathology in regions of the brain with high levels of
dopamine, such as the basal ganglia and substantia nigra [27–
32]. Dopamine acts principally through dopamine receptors (DR),
G-protein coupled receptors (GPCR) that are divided into D1-like
DR (D1R and D5R) and D2-like DR (D2R, D3R and D4R)
depending upon whether they activate (D1-like DR) or inhibit
(D2-like DR) adenylyl cyclase [33]. Studies show that DR also
activate alternative pathways, including mobilization of calcium
from the endoplasmic reticulum [34–37]. The effects of dopamine
on macrophage function, and the signaling pathways by which
these effects are mediated, have not been studied extensively.
Our previous studies showed that dopamine increases HIV
replication in human macrophages through activation of DR,
increasing the total number of infected cells [38]. The mecha-
nism(s) by which this occurred are unclear, but one possibility is by
increasing HIV entry into macrophages. HIV entry is complex,
and in macrophages, it is mediated by the interaction of the viral
envelope protein gp120 with the surface receptor CD4 and co-
receptor CCR5 [39]. In this study, we examined whether
dopamine increases HIV entry and whether that increase was
mediated by changes in CCR5 expression and/or activation of
DR.
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Our data showed that dopamine increased HIV entry into
human primary monocyte-derived macrophages (MDM) by
approximately 2-fold, and that the increased entry occurred at
dopamine concentrations above 1028 M. The increased entry
required CCR5, but was not mediated through changes in the
surface expression of this receptor. Increased entry also required
activation of DR and was mediated by both D1-like and D2-like
DR, suggesting that a common DR signaling mechanism mediates
the increased entry. Using transfected HEK293 cells, we
demonstrated that calcium mobilization resulting from activation
of Gaq-coupled receptors, such as CCR5 [40], can be potentiated
by both D1-like and D2-like DR. These data indicate that the
dopamine-induced increase in macrophage HIV replication we
previously reported is due, at least in part, to an increase in viral
entry, and suggest that this could be a result of a dopamine-
mediated increase in calcium mobilization.
Methods
Reagents
RPMI-1640, penicillin/streptomycin (P/S), 10X HEPES and
10X HBSS from Life Technologies (Carlsbad, CA). Human AB
serum from Lonza (Basel, Switzerland). Fetal Bovine Serum from
Lonza for MDM culture and from Gemini (West Sacramento, CA)
for HEK293 culture. BSA, Acetylcholine, Probenecid, Dopamine,
SKF81297, Sulpiride and SCH23390 from Sigma-Aldrich (St.
Louis, MO). SKF38393 and Flupenthixol dihydrochloride from
Tocris Biosciences (Minneapolis, MN). Quinpirole from Tocris or
Sigma-Aldrich. All DR agonists and antagonists were resuspended
in distilled H2O. TAK779 was obtained through the NIH AIDS
Reagent Program, Division of AIDS, NIAID, NIH [41].
Macrophage colony stimulating factor (M-CSF) was from
Peprotech (Rocky Hill, NJ), and was resuspended at 100 mM in
distilled H2O.
Cell isolation and culture
Human peripheral blood mononuclear cells (PBMC) were
separated from blood obtained from healthy donors (New York
Blood Center, Long Island City, New York) by Ficoll-Paque (GE
Healthcare, Piscataway, NJ) gradient centrifugation. Monocytes
present in the PBMC were determined by flow cytometry of
CD14+ cells in the PBMC using a FACS Canto II flow cytometer
(Becton-Dickinson, Franklin Lakes, NJ). Monocyte derived mac-
rophages (MDM) were obtained by adherence isolation, through
culture in macrophage media (RPMI-1640 with 10% FCS, 5%
human AB serum, 10 mM HEPES, 1% P/S, and 10 ng/mL M-
CSF) for 3 days, washing and culturing another 3–5 days. After 6–
8 total days in culture the cells were considered to be mature
MDM. Flp-In T-Rex HEK 293 cells (HEK 293 cells, Life
Technologies) were maintained in DMEM supplemented with
10% FBS and 2 mM L-glutamine (Life).
Generation of Viral Stocks
Viral DNA was prepared by isolating plasmids from bacterial
stocks (HB101 cells, Life Technologies) transformed with viral
DNA clones and purified using CsCl2 gradient ultracentrifugation.
Stocks of HIVBaL and HIVBaL harboring Vpr-b-lactamase were
prepared in parallel by co-transfecting 3 mg of HIVBaL DNA
(obtained through the NIH AIDS Reagent Program, Division of
AIDS, NIAID, NIH: pWT/BAL), along with 15 mg of either
pcDNA or pMM310 (a plasmid expressing Vpr-b-lactamase,
obtained through the NIH AIDS Reagent Program, Division of
AIDS, NIAID, NIH: pMM310 (Cat#11444) from Dr. Michael
Miller [42]) into HEK 293 cells using calcium phosphate
precipitation as described by the manufacturer (Chemicon). A
100% HEK 293 cells were split 1:6 in a 10 cm2 plate 24 hours
prior to transfection, with the goal of 30–40% confluency at the
time of transfection. Media was changed at 16 hours post-
transfection and collected 24 and 48 hours later. Supernatant was
passed through a 0.45 mm cellulose acetate syringe filter (Corning,
Tewksbury, MA), and treated with 20 U/ml DNAseI (Roche,
Indianapolis, IN) for 30 minutes at 37uC. Viral stocks were
purified and concentrated by passing the virus through 20%
sucrose/PBS gradient centrifugation for 2 hr at 36,000 rpm, 4uC,
and then viral pellets were resuspended in macrophage media and
stored in aliquots at 70uC. To insure Vpr-b-lactamase virions
maintained infectivity, they were tested by infecting MDM and
compared to infections with non-Vpr-b-lactamase containing viral
stock. Analysis of p24 production in response to infection showed
no significant difference in infectivity of virus with and without
Vpr-b-lactamase (data not shown). To Infectious units in each
viral stock were determined by infection of Hi-5 GHOST cells
(obtained through the NIH AIDS Reagent Program, Division of
AIDS, NIAID, NIH: GHOST Cell Transfectants - GHOST (3)
Hi-5 from Dr. Vineet N. KewalRamani and Dr. Dan R. Littman
[43]). Determination of the infectious units in each viral stock
enabled inoculation using multiplicity of infection (MOI), insuring
that all infections were performed with identical numbers of
infectious virions per macrophage.
Viral Entry Assay. Entry assays were performed using the
Geneblazer in vivo detection kit (Life Technologies) according to
the manufacturers protocol, with optimization for use in primary
macrophages as previously described [44]. Mature MDM cultured
in flat, clear bottom 96 well black plates (ThermoFisher Scientific,
Waltham, MA) were infected in quadruplicate with HIVBaL
containing Vpr-b-lactamase, at a multiplicity of infection (MOI) of
0.002, 0.005 or 0.01, based on the CD14+ cells in the starting
PBMC population. MDM were incubated for 2.5 or 4 hours at
37uC with 5% CO2. Dopamine or DR agonists were added
concurrently with HIV, while the pan-DR antagonist flupenthixol
was added 30 minutes prior to addition of virus. All DR agonists
were used at 108 M, as our preliminary studies indicated that this
was the concentration that induced a significant increase in entry
in the greatest number of donors. After incubation, MDM were
washed and incubated in the dark at RT for 6 hours in 100 ml of
phenol red free macrophage media and 20 mL of 6X CCF2-AM
loading solution (Loading solution ratios optimized for primary
macrophages as follows; 0.04:0.36:0.25:1,935 A:B:D:C). CCF2-
AM contains two fluorophores connected by a lactam ring, and
generates green fluorescence by means of fluorescence resonance
energy transfer (FRET) when the fluorophores are in close
proximity. When the lactam ring is cleaved, the FRET interaction
is disrupted and the fluorescence becomes blue. In this assay,
uninfected cells fluoresce green because the lactam ring is intact
and infected cells fluoresce blue because the b-lactamase enzyme
contained within the infecting virus cleaves the lactam ring and
separates the fluorophores [45].
After incubation at RT, 12 images of each infection condition
were generated using a Zeiss IX70 inverted microscope (Zeiss) and
an Olympus E-620 Live View DSLR (Olympus). Volocity (Perkin-
Elmer) was used to enumerate the number of infected (blue) and
uninfected (green) cells in each condition. Primary cells from
different donors have varying susceptibility to HIV infection,
therefore the number MDM infected with HIV was variable
between experiments. There was also inter-experiment variation
in the effects of different concentrations of dopamine on HIV
entry, likely due to donor dependent differences in the response to
dopamine. To evaluate changes in HIV entry induced by each
Dopamine Increases HIV Entry into Macrophages
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concentration of dopamine, in each donor we compared the
macrophages infected in the presence of each concentration of
dopamine or agonist to the macrophages infected in control
infections (those cultures infected with HIV alone). The mean
difference in the number of cells infected is determined by the
formula, 100x (Experimental – Control) / Control, and expressed
as percent increase in macrophage infection relative to the control
infection (HIV alone), which is defined as a 0% increase.
Flow Cytometry
CD14+ cells present in isolated PBMC were determined using
anti-human CD14-PE (clone M5E2, BD Biosciences, Franklin
Lakes, NJ) and an isotype matched negative control, IgG2a-PE (BD
Biosciences). PBMC were stained for 30 minutes at 4uC, washed
with 1% BSA in PBS and fixed with 2% paraformaldehyde
(Electron Microscopy Sciences, Hatfield, PA). Immunopositive
cells were analyzed by acquisition of 10,000 events on a FACS
Canto II flow cytometer and analyzed using FlowJo (Treestar,
Ashland OR). To analyze CD4 or CCR5 protein expression on
the macrophage surface, MDM were detached from culture dishes
with TrypLE Select (10X) for 30 minutes at 37uC, followed by
gentle agitation and scraping. 1–26105 MDM were stained for
CCR5 or CD4 using anti-human CCR5-APC/Cy7 and CD4-
FITC, with the isotype-matched negative controls, IgG1-APC/
Cy7 or IgG1-FITC (BD Biosciences). Antibodies were titrated to
determine the optimal concentration for staining PBMC and
MDM. After subtracting out the background fluorescence from
the isotype matched control, the mean fluorescence intensity (MFI)
for each antigen was determined.
Generation of Dopamine Receptor Expressing HEK Cells
Stable cell lines were generated as previously described (Han et
al. 2009). Briefly, Flp-In T-Rex 293 cells (Life Technologies) were
transfected with either D1R or D2R expressing plasmids using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
protocol. Transfected HEK cells were selected and maintained in
media with G418 (Mediatech, Manassas, VA) or Hygromycin B
(Mediatech) for expression selection. Single colonies were isolated
and screened for receptor expression using FACS analysis. D2s
stable line refers to cells transfected with the D2R expressing
plasmid SF-D2s, while D1 stable line refers to cells transfected for
inducible expression of D1R expressing plasmid, 3xHA-D1. The
D1-D2s double stable line refers to HEK cells stably transfected
with 3xHA-D1 and SF-D2 plasmids. Cells with inducible receptors
were incubated in 1 mg/ml tetracycline-containing medium
overnight prior to experiments to induce expression. Generation
of these cell lines enabled maintenance of consistent receptor
expression levels for calcium flux assays.
Measurement of Calcium Flux
Calcium flux was measured using the Flipr Calcium 5 Assay kit
(Molecular Devices, Sunnyvale, CA) and according to the
manufacturers protocol. Briefly, cells were resuspended in HBSS
buffer containing 20 mM HEPES and 2.5 mM probenecid and
distributed in 40 ml volumes in 96 well plates (500,000 cells/well).
Fifty ml Flipr5 dye (Molecular devices) was added to each well and
plates were incubated in 37uC 5% CO2 for 1 hour. Plates
containing 10x concentrated ligand were prepared in HBSS with
20 mM HEPES. During the calcium reading, performed on a
Flexstation 3 (Molecular Devices), 10 ml ligand was injected to the
well at the indicated times. Intracellular calcium levels were
measured every 2 sec over the course of 220 sec. Data was
analyzed by Softmax Pro 5.4 (Molecular Devices) and Prism 6.0
(Graphpad, La Jolla, CA).
Statistics
Statistics were determined using Prism 6.0. Entry assay and flow
cytometry data were analyzed for normality using a D’Agostino
and Pearson omnibus normality test. Normally distributed were
analyzed using a two-tailed Student’s T-test and data that were not
normally distributed were analyzed with Wilcoxen Matched Pairs
Signed Rank Test. P , 0.05 was considered significant.
Results
Dopamine Increases HIV Entry into Primary Human
Macrophages
To determine whether dopamine-mediated increases in HIV
replication in macrophages were due to an increase in viral entry,
primary human MDM were infected with different concentrations
of HIVBaL virions harboring an active b-lactamase enzyme (b-lac
HIV). As described in the methods, entry of b-lac HIV into a
macrophage causes that cell to fluoresce blue, while uninfected
cells remain green. The percentage of viral entry was quantified by
counting the number of blue and green cells and comparing the
number of blue cells to the total cell number. Infection with b-lac
HIV using a multiplicity of infection (MOI) of 0.002 for 4 hours
resulted in infection of 1.0% to 11.9% of MDM, 1.3% to 27.4%
using an MOI of 0.005 and 1.4% to 37.8% of cells using an MOI
of 0.01 (Figure 1A, MOI 0.002, n = 11; 1B, MOI 0.005, n = 6; 1C,
MOI 0.01, n = 16). The variation in the susceptibility of
macrophages to infection with HIV demonstrates the heteroge-
neity of primary macrophages from different donors used in these
studies. Treatment with dopamine significantly increased viral
entry into MDM at all concentrations of HIV tested (MOI 0.002
(1A), 0.005 (1B) and 0.01(1C)). The magnitude of the dopamine-
mediated increase in HIV entry resulting from infection with each
concentration of HIV is shown in Figure 1D (MOI 0.002, 117%
increase, n = 11, p = 0.001***; MOI 0.005, 135% increase, n = 6,
p = 0.0313 *; MOI 0.01, 75% increase, n = 16, p = 0.0002 ***).
These data indicate that the effect of dopamine on HIV entry is
not dependent on the concentration of the infecting virus. In
Figure 1D and subsequent figures showing a percent increase, the
control infections (HIV alone) are defined as a 0% increase, as
described in the Methods. A representative experiment showing
MDM from a single donor infected with b-lac HIV at an MOI of
0.01 for 4 hours in the presence and absence of dopamine is shown
(Figures 1E and 1F). Uninfected cultures showed no blue
fluorescence, indicating that blue fluorescence was specifically
induced by HIV entry (Figure 1G). Donor dependent differences
among primary macrophages resulted in inter-experiment varia-
tion in baseline levels of HIV infection and in the magnitude of the
increase in entry mediated by different concentrations of
dopamine. To account for this variability, each infection was
performed with 4 different concentrations of dopamine, 26108 M,
26107 M, 26106 M and 26105 M, to ensure that cells from each
donor were treated with a concentration of dopamine that induced
an optimal response. For each donor, the dopamine concentration
that induced the maximal increase in entry was used for analysis.
To characterize further the effects of dopamine on entry, b-lac
HIV (MOI 0.01) was added to MDM for 2.5 hours in the presence
of 8 different concentrations of dopamine, ranging from 1010 M to
105 M. Infection time was decreased to 2.5 hours to maximize the
detection of the changes in entry, and MOI of 0.01 was used
because this concentration provided the most consistent infection
among donors. In experiments using cells derived from 32
different donors, addition of 0.01 MOI of b-lac HIV for 2.5
hours resulted in infection of 12.1 +/ 1.5% of MDM. The mean
percentage of macrophages infected with HIV was significantly
Dopamine Increases HIV Entry into Macrophages
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increased in the presence of the four highest concentrations of
dopamine, 108, 107,106 and 105 M, (Figure 2, 108 M DA, 72%
increase, n = 32, p , 0.0001 ****; 107 M DA, 73% increase,
n = 21, p = 0.0005 ***; 106 M DA, 115% increase, n = 15, p ,
0.0001 ****; 105 M DA, n = 13, p = 0.0171 *). Although a few
donors showed increases in entry in response to concentrations of
dopamine below 108 M dopamine, the mean amount of entry in
MDM treated with less than 108 M dopamine was not significantly
increased above the control infection with HIV alone (Figure 2, p
. 0.05 for all conditions, 1010 M DA, n = 15; 109 M DA, n = 21;
26109 M DA, n = 10; 56109 M DA, n = 10). These data show
that the dopamine-mediated increase in HIV entry into macro-
phages is dose dependent with a steep threshold, only occurring at
concentrations of 108 M or greater of dopamine.
Dopamine-Mediated Increase in HIV Entry Requires CCR5
In macrophages, HIV entry is generally mediated by binding of
gp120 to CD4 and CCR5 on the plasma membrane, which
initiates fusion of the viral membrane with the cell membrane
[39]. Expression of CCR5 correlates with macrophage suscepti-
bility to HIV [46–48] and increased surface CCR5 can mediate
increased HIV infection [49–51]. Therefore, dopamine-treated
macrophages were evaluated for changes in surface CCR5 by flow
cytometry. MDM were treated with dopamine for 2.5 hours in the
presence or absence of HIV infection, and MDM not treated with
dopamine were used as controls. Dopamine concentrations of
106 M and 109 M were selected as representative concentrations
that did or did not increase HIV entry, respectively. Neither
concentration of dopamine increased surface CCR5 in HIV-
infected MDM (Figures 3A, 3B, n = 7) or in uninfected MDM,
and HIV infection alone did not increase CCR5 expression (data
not shown). These data indicate that dopamine does not increase
HIV entry into macrophages by increasing surface CCR5.
Macrophages were also examined by flow cytometry for dopa-
mine-mediated changes in surface CD4. However, CD4 receptor
expression on MDM was low and varied among donors, and we
were not able to quantify reliably these data (data not shown).
In the CNS, where macrophages could be exposed to high
concentrations of dopamine, R5-tropic viruses predominate [52–
54]. However, in addition to CCR5-mediated entry, HIV can
enter macrophages through alternative pathways such as the
endocytic pathway or through interaction with the co-receptor
CXCR4 or minor co-receptors including CCR3 [53,55–60]. To
determine whether dopamine increases viral entry by enabling
HIV to use a CCR5-independent entry mechanism, we examined
dopamine-mediated changes in entry in the presence of a CCR5
inhibitor. Macrophages were pretreated with the CCR5 inhibitor
TAK779 (2 6107 M) for 1 hour, then TAK779 treated and
untreated MDM were infected with 0.01 MOI of b-lac HIV in the
presence or absence of 108 M dopamine. Dopamine treatment
significantly increased HIV entry relative to cells infected with
Figure 1. Dopamine increases HIV entry into primary human macrophages. Primary human monocyte derived macrophages were infected
with 3 concentrations of b-lac HIV (MOI of 0.002, 0.005, 0.01) in the presence of either 26108 M, 26107 M, 26106 M or 26105 M dopamine, and
control cells were infected with HIV alone. In panels A-C each circle or square represents infection of macrophages from a single donor. Dopamine
significantly increased viral entry in macrophages infected with all concentrations of HIV (A, MOI 0.002, n = 11, ** p = 0.0002), 0.005 (B, n = 6, *
p = 0.0313) or 0.01 (C, MOI 0.01, n = 16, *** p = 0.001) after 4 hr incubation. Panel D shows the percent increase in entry mediated by dopamine in
infections with each concentration of HIV relative to control (MOI 0.002 vertical lines, MOI 0.005 diagonal lines, MOI 0.01, horizontal lines). Panels E - G
show representative images of cultures infected with 0.01 MOI b-lac HIV in the presence of (E) dopamine, (F) HIV alone, (G) and uninfected
macrophages. White arrows indicate infected cells.
doi:10.1371/journal.pone.0108232.g001
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HIV alone (Figure 3C, n = 6,108 M DA, 66.4% increase,
p = 0.0194 *). Blocking CCR5 with TAK779 abrogated HIV
entry in pretreated cultures infected with both HIV alone and with
HIV + dopamine (Figure 3C, n = 6, HIV + TAK779, 94.5%
decrease, p = 0.0001 **, HIV + TAK779 + DA, 95.5% decrease,
p = 0.0003 ***). These data demonstrate that the dopamine-
mediated increase in entry requires CCR5 and suggest that
dopamine does not act through a CCR5-independent entry
pathway.
Increase in HIV Entry is Specifically Mediated by
Activation of Dopamine Receptors
Studies in rodents show that dopamine can activate other types
of receptors in addition to DR [61,62]. To determine whether the
dopamine-induced increase in HIV entry is specifically mediated
by activation of DR, we examined entry in the presence of the
pan-DR antagonist flupenthixol. This molecule binds to all DR
with high affinity (Ki , 8610
8 M for all DR, [63–65]), and should
interfere with the binding of dopamine to these receptors.
Macrophages were infected with of b-lac HIV (0.01 MOI) and
concurrently treated with 109 M, 108 M, 107 M and 106 M
dopamine. Infections were performed in presence or absence of
106 M flupenthixol, added 30 minutes prior to the addition of b-
lac HIV and dopamine. The presence of 108 M, 107 M and 106 M
dopamine significantly increased viral entry (Figure 4, n = 7 for all
concentrations of dopamine, 108 M DA 76% increase, p = 0.0156
*; 107 M DA 93% increase, p = 0.0469; 106 M DA, 102%
increase, p = 0.0156 *). Pretreatment with flupenthixol abrogated
this effect, significantly reducing HIV entry in the presence of
107 M (p = 0.0313 *) and 106 M dopamine (p = 0.0313 *).
Fluxpenthixol did not significantly decrease the effect of 108 M
dopamine, although infections in the presence of 108 M dopamine
showed a large decrease in entry that trended toward significance
(p = 0.0781). Flupenthixol treatment did not affect viral entry in
MDM not treated with dopamine. These data demonstrate that
activation of DR is necessary for the dopamine-mediated increase
in HIV entry.
Our previous data showed that activation of D2-like DR
increased viral replication [38], and more recent experiments
demonstrated that D1-like DR activation did so as well (P.J.
Gaskill and J.W. Berman, unpublished data). To determine the
subtypes of DR that mediate the effects of dopamine on HIV
entry, MDM were infected with 0.01 MOI of b-lac HIV in the
presence of either dopamine, SKF 38393 (D1-like DR agonist),
Quinpirole (D2-like DR agonist) or both SKF and Quinpirole
together. Dopamine and all agonists were added at a concentra-
tion of 108 M. Dopamine, SKF 38393 and Quinpirole each
significantly increased HIV entry into macrophages (Figure 5,
n = 10 for all agonists, Dopamine, 79% increase, p = 0.0039 **;
SKF 38393 110% increase, p = 0.0342 *; Quinpirole, 91%
increase, p = 0.0098 **). Infection in the presence of agonists for
both D1-like and D2-like DR together also significantly increased
entry, but did not enhance the increase in entry beyond that seen
for each agonist individually (Figure 5, n = 10, SKF 38393 + Quin,
92% increase, p = 0.0375 *). The magnitude of the increase in
entry did not differ significantly among any of these DR ligands.
These experiments demonstrate that the activation of either D1-
like or D2-like receptors mediates increased HIV entry into
macrophages. The lack of an additive or synergistic effect could
indicate that the two types of DR act through a common signaling
pathway to increase HIV entry.
Activation of Both D1-like and D2-like Dopamine
Receptors Potentiates Calcium Mobilization Triggered by
Prior Activation of Gaq-Coupled GPCR
That HIV entry is increased by both D1-like and D2-like DR
suggests the possibility that they do so through a common signaling
pathway. Although D1-like and D2-like receptors have opposite
effects on cAMP production, they have both been reported to
cause calcium mobilization. Calcium is important for HIV
infection; it is induced by binding of gp120 to CCR5 on
macrophages [66,67], and calcium mobilization mediated by
activation of the inositol triphosphate receptor (IP3R) in the
endoplasmic reticulum is required for HIV entry [68]. Both
Figure 2. Increase in HIV entry requires a minimum threshold of dopamine. MOI 0.01 b-lac HIV was added to macrophages in the presence
of 1010, 109, 26109, 56109, 108, 107, 106 M and 105 M dopamine and control cells were infected with HIV alone. Relative to control infections, viral
entry was significantly increased when MDM were infected with HIV in the presence of 108, 107, 106 M and 105 M dopamine (n = 1032, ** p, 0.01, ***
p , 0.001 vs. HIV only) but not in the presence of 1010, 109, 26109, or 56109 M dopamine. There was no significant difference in the magnitude of
the increase in entry among cultures infected the presence of 108, 107, 106 M and 105 M dopamine.
doi:10.1371/journal.pone.0108232.g002
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subtypes of DR have been reported to mediate calcium release
from the endoplasmic reticulum through a potentiation mecha-
nism, D1-like DR through activation of protein kinase A [69], and
D2-like DR through interaction with phospholipase C (PLC) and
calcyon [70]. In this process, activation of DR evokes an increase
in Ca2+ mobilization following an initial Ca2+ release mediated by
activation of a Gaq-coupled receptor, such as CCR5. In addition,
in cells heterologously expressing both D1R and D2R, coactiva-
tion of both receptor subtypes can initiate calcium release through
Gbc-mediated signaling [35]. Thus, a common pathway through
which both D1-like and D2-like DR could mediate calcium flux is
Gbc activation of PLCb, as activation of both subtypes of DR
release Gbc subunits. This would enable activation of both
subtypes of DR to increase HIV entry by potentiating the Ca2+
mobilization required for the entry process. To determine whether
both D1-like and D2-like DR could increase calcium mobilization
through potentiation of Gao signaling, we examined calcium flux
in HEK293 cells stably transfected with D1R, D2R, or both
dopamine receptors.
To determine whether DR activation in the absence of Gao
activation induced calcium flux, parental HEK cells or cells
transfected with either D1R or D2R were treated with 105 M
dopamine (Figure 6, black curves). These experiments showed that
dopamine alone did not induce any calcium release. The Gaq-
mediated calcium response was tested using 105 M acetylcholine
(ACh) to stimulate endogenous Gaq-coupled muscarinic receptors
(M3) expressed in HEK cells [71] (Figure 6, red curves).
Treatment with acetylcholine resulted in a clear pattern of
prolonged (. 60 secs to subside) internal calcium release, with
kinetics consistent with IP3R-mediated calcium mobilization [72].
This ACh-induced calcium flux was specific to muscarinic
receptor activation as it was blocked by the muscarinic receptor-
specific antagonist pirenzepine (data not shown).
Figure 3. CCR5 is necessary for dopamine-mediated increase in HIV entry. Macrophages were infected with HIVBaL in the presence of 10
9 M
or 106 M dopamine and analyzed by flow cytometry for CCR5. (A) A representative histogram of CCR5 surface expression in a single donor in
response to HIV alone (IgG – dashed grey lines, CCR5 – solid grey lines) is shown. (B) The mean MFI of CCR5 on the surface of macrophages from
seven donors infected with HIV alone (white), HIV + 109 M DA (light gray) or HIV + 106 M DA (dark gray) relative HIV alone. Neither concentration of
dopamine-induced significant changes in the expression of this protein on the cell surface relative to the macrophages infected with HIV alone. (C)
Macrophages were pretreated with 26107 M TAK779, and then an MOI of 0.01 b-lac HIV was added in the presence or absence of 108 M dopamine.
As controls, both macrophages pretreated with TAK779 and macrophages not pretreated were infected with HIV alone. Dopamine significantly
increased HIV entry (n = 6, p = 0.0194 *), and pretreatment with 26107 M of the CCR5 inhibitor TAK779 blocked HIV entry into macrophages infected
in both the presence and absence of dopamine (HIV + TAK779, p = 0.0001 **, HIV + TAK779 + DA, p = 0.0003 ***).
doi:10.1371/journal.pone.0108232.g003
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Once Gaq-mediated calcium release was defined, we deter-
mined whether 105 M dopamine, which was inactive alone, could
potentiate the effect of 105 M ACh if added 80 seconds later.
Treatment with dopamine following Gaq stimulation induced a
second calcium response in cell lines expressing either D1R or
D2R, but not in the control parental HEK cells (Figure 6, blue
curves). In all of the cell lines, pretreatment with 105 M U73122, a
potent inhibitor of PLC [73], abrogated the ACh-mediated
calcium mobilization, as well as the subsequent dopamine-
mediated potentiation effect. (Figure 6, green curves). To validate
Figure 4. Activation of dopamine receptors required for the dopamine-mediated increase in HIV entry. Macrophages were pretreated
with the pan-dopamine receptor (DR) antagonist flupenthixol (flux, 106 M) and then MOI 0.01 b-lac HIV was added concurrently with either 109, 108,
107 and 106 M dopamine. As controls, both vehicle treated and flupenthixol treated cells were infected with HIV alone. Solid columns represent
infections in the presence of dopamine, while hatched columns to the right of each solid column of the same color represent infections in presence
of an identical concentration of dopamine as well as flupenthixol. There was a significant increase in viral entry into macrophages infected with HIV
the presence of 108, 107 and 106 M dopamine (n = 7 for all concentrations of dopamine, * p , 0.05 vs. HIV only). This increase was blocked by
flupenthixol treatment, and entry was significantly reduced in the presence of 107 and 106 M dopamine (n = 7, # p , 0.05 vs. identical concentration
of dopamine without flupenthixol).
doi:10.1371/journal.pone.0108232.g004
Figure 5. Activation of both D1-like and D2-like dopamine receptors is capable of mediating increased HIV entry. Macrophages were
infected with b-lac HIV (MOI 0.01) in the presence of either 108 M dopamine (light gray), a D1-like DR agonist (108 M SKF 38393, dark gray), a D2-like
DR agonist (108 M Quinpirole, white), both SKF 38393 and Quinpirole together (horizontal lines). Macrophages infected with HIV alone served as
controls. Dopamine, SKF 38393, Quinpirole and SKF 383893 + Quinpirole all significantly increased viral entry relative to infections with HIV alone
(n = 10, * p . 0.05, ** p . 0.01 vs. HIV alone).
doi:10.1371/journal.pone.0108232.g005
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the involvement of D1R and D2R in calcium release, selective
agonists as well as antagonists were used. Using HEK cells
expressing either D1R or D2R, the potentiation of Gaq-mediated
calcium release was triggered and blocked by their cognate
agonists and antagonists (105 M SKF81297 and SCH23390 for
D1R and 105 M Quinpirole and Sulpiride for D2R) respectively
(Figure 7A, B). These results demonstrate the existence of specific
D1-like and D2-like DR-dependent mechanisms for potentiation
of Gaq-mediated calcium mobilization through PLC activation.
Discussion
Increases in CNS dopamine and damage to the dopaminergic
system correlate with HIV-associated neuropathogenesis and
HAND [31,32], but the mechanisms underlying these correlations
are not well understood. Prior to the use of combinatorial anti-
retroviral therapy (cART), increased amounts of HIV DNA [74]
and increased neuropathology were found in regions of the brain
innervated by dopaminergic neurons, especially the basal ganglia
[27,28,30,75]. In SIV-infected macaques, treatment with Selegi-
line, L-DOPA or methamphetamine, all of which elevate CNS
dopamine, increased viral replication in the CNS and exacerbated
neuropathology [25,26,76]. These data indicate strong connection
between the dopaminergic system and the development of
neuropathology and HAND. Our laboratory showed that
dopamine increases HIV infection in macrophages, and alters
macrophage production of inflammatory cytokines [38,77].
Although astrocytes can be infected with HIV [8,11,12],
macrophages and other cells of the monocytic lineage are the
primary target cells for the virus in the CNS [7–10]. This indicates
that the impact of dopamine on HAND may be mediated, at least
in part, by its effects on macrophage infection [78]. Thus, defining
the mechanism by which dopamine increases HIV infection of
these cells is important to understanding the effects of drug abuse
on the development HAND.
This study demonstrates that dopamine significantly increases
the entry of HIV into primary human macrophages across a range
of concentrations of the infecting virus. This effect showed a very
steep concentration dependence such that at and above 108 M
Figure 6. Dopamine receptors potentiate Gaq-receptor mediated calcium flux through phospholipase C. Intracellular calcium levels
were measured every 2 seconds for 220 seconds and plotted against time. Ca2+ level is shown in percentage normalized to the initial 105 M
acetylcholine (ACh) added at 20 seconds. Vehicle (red curve), 105 M dopamine (DA, blue curve), or 105 M DA with 105 M U73122 (PLC inhibitor, green
curve) was added at 100 seconds following 105 M ACh at 20 secs, indicated by arrows. As a negative control, vehicle followed by 105 M DA was also
measured (black curve). Experiments were performed in parental (A) HEK cells, (B) D1R expressing cells, and (C) D2R expressing cells. Traces are
representatives of n = 3 experiments.
doi:10.1371/journal.pone.0108232.g006
Figure 7. Potentiation of Gaq-mediated calcium flux is induced specifically by activation of D1-like and D2-like dopamine receptors.
Intracellular calcium levels were measured every 2 seconds and plotted against time. Ca2+ level is shown in percentage normalized to the initial 105 M
acetylcholine (ACh) added at 20 secs. (A) In D1 stable cells, either vehicle control (black curve), 105 M SKF81297 (D1 agonist, red curve), or 105 M
SKF81297 with 105 M SCH23390 (D1 antagonist, blue curve) was added at 100 secs following 105 M ACh at 20 secs, indicated by arrows. (B) In D2
stable cells, either vehicle control (black curve), 105 M Quinpirole (D2 agonist, red curve), or 105 M Quinpirole with 105 M Sulpiride (D2 antagonist,
blue curve) was added at 100 secs following 105 M ACh at 20 secs, indicated by arrows. Traces are representatives of n = 3 experiments.
doi:10.1371/journal.pone.0108232.g007
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dopamine the increase in entry was of similar magnitude. The
mechanism(s) underlying this steep dose dependence is unclear.
The concentration of dopamine that CNS macrophages may be
exposed to in the human brain is difficult to determine, but based
on studies in animal models, basal dopamine levels in the CNS are
estimated to be in the low nanomolar range, although some studies
suggest they may be higher, particularly during active neurotrans-
mission [79–82]. Dopamine concentrations also vary regionally
within the CNS [83,84], and the amount of dopamine to which
macrophages could be exposed depends on the area of the brain in
which they reside and the type of stimulation initiating the
dopamine release [85–87].
The use of illicit drugs, alcohol, and certain therapeutic agents
significantly increases dopamine [88–95]. The greatest elevation of
dopamine concentrations occur within the basal ganglia, specif-
ically in the striatum and nucleus accumbens, as well as in the
ventral tegmental area and substantia nigra, which contain the
dopaminergic cell bodies [87,96]. Dopaminergic communication
is mediated by volume transmission, causing dopamine to suffuse
the tissue and extracellular space surrounding the releasing
neurons [97–99]. Depending on the region, neurotransmission
can evoke dopamine concentrations above 108 M at substantial
distance from the synapse at which the dopamine was released.
Using animal models, this distance is estimated to be 7–20 mm in
the striatum and 6–10 mm in the nucleus accumbens [80,97,99–
102]. Thus, CNS macrophages in these regions could encounter
dopamine as it effluxes from the synapse or when it is released
extrasynaptically [80,85,87,103,104]. Use of drugs that increase
CNS dopamine concentrations significantly expand the radius of
dopamine diffusion [85]. Thus, in the CNS of drug abusers, the
increased volume of tissue containing higher concentrations of
dopamine would expose greater numbers of macrophages to
dopamine as it diffuses into a larger area surrounding dopami-
nergic neurons affected by drugs of abuse.
The concentration of dopamine released in response to different
drugs depends on the mechanism of action of the drug [94,105],
the age of the user [106], and the nature of the drug use, as there
are large differences in dopamine response between chronic drug
abusers and intermittent or naive users [107–109]. Some studies
show that chronic drug use decreases drug-induced dopamine
release [91,107,110,111], suggesting that macrophages in the CNS
of chronic drug users are less likely to be exposed to dopamine
levels high enough to increase viral entry. However, acute and
intermittent drug use could expose CNS macrophages to
dopamine concentrations greater than the threshold at which
dopamine increases HIV entry. Overall, these data suggest
elevation of CNS dopamine may be a common mechanism by
which different types of drugs increase HIV infection of
macrophages and thereby contribute to neuropathogenesis and
the development of HAND.
HIV infection is initiated by the entry of the virus into the target
cell. In macrophages, viral entry is mediated by the interaction of
the HIV envelope protein, gp120, with CD4 and a chemokine
receptor, generally CCR5 [39]. The majority of viruses in the
CNS, where macrophages would encounter the higher concen-
trations of dopamine induced by drug abuse, use CCR5
[53,54,112,113], although it has been suggested that X4 viruses
may infect macrophages in the later stages of HIV neuropatho-
genesis [52]. Increases in surface CCR5 can increase HIV
infection [49,50,114], but neither 109 M nor 106 M dopamine
significantly altered surface expression of CCR5. These results
indicate that dopamine does not mediate its effects on entry by
increasing the expression of CCR5, and suggest the possibility that
dopamine may increase entry into macrophages through a CCR5-
independent entry pathway, such as use of alternate co-receptors
or endocytosis [55–58]. However, treatment with the CCR5
inhibitor TAK779 abrogated viral entry in both the presence and
absence of dopamine.
These results indicate that the increase in entry is not mediated
through a CCR5-independent entry pathway, as increased entry
by means of this alternative pathway would not have been blocked
by inhibition of CCR5. Thus, dopamine may induce other
changes that enhance the entry process. Macrophage-tropic HIV
from the CNS can exhibit conformational changes in gp120 that
enable these viruses to infect more efficiently cells with low surface
CD4 [53,113,115], such as macrophages and microglia [116,117].
Increases in surface CD4 also increase viral replication [49,114].
Therefore, a dopamine-mediated increase in this receptor could
increase HIV entry. We examined CD4 expression on MDM and
found that surface CD4 was low and varied in different donors.
While we were unable to quantify these data reliably, they did
suggest that dopamine does not increase surface CD4.
Another possibility is that dopamine-mediated changes in
CCR5 could increase viral entry. CCR5 is present on the cell
surface in multiple conformational states [118], and studies show
different conformations of this receptor increase the binding
affinity or accessibility of CCR5 to HIV, changing the efficiency of
entry or fusion [119–121]. In macrophage-tropic CNS viruses,
changes in the interaction of gp120 with the 1st and 2nd
extracellular loop regions and the N-Terminus increased the
efficiency of HIV infection [120]. Thus, dopamine-mediated
changes in the expression or abundance of specific conformations
of CCR5 on the macrophage surface could be responsible for the
increase in HIV entry. Our study used a single virus strain derived
from the lung, HIVBaL, so it is unclear whether dopamine-
mediated changes in the conformation CCR5 could affect the
entry of other strains of HIV. However, we found previously that
dopamine increases the replication of HIVADA and HIVYU2 [38],
viruses that were derived from the blood and brain, respectively
[122,123], suggesting that dopamine-mediated changes in CCR5
could increase HIV entry of R5 viruses derived from many
different compartments.
In addition to CCR5, the dopamine-mediated increase in HIV
entry requires DR activation and is mediated by D1-like and D2-
like DR, suggesting a signaling pathway common to both subtypes
of DR. The major pathway activated by DR is the modulation of
cAMP, D1-like DR activating adenylyl cyclase through Gas/olf,
and D2-like DR inhibiting it through Gai/o [33,34]. However, D1-
like and D2-like dopamine receptors have opposing effects on the
regulation of cAMP activity, making it less likely that this pathway
is mediating the change in HIV entry. One signaling mechanism
common to both D1-like and D2-like dopamine receptors is
calcium mobilization, although it is unclear if calcium flux occurs
through monomeric DR or heteromeric D1R–D2R complexes
[35,124]. The interaction of gp120 with CCR5 induces calcium
mobilization [66,67,125,126], and CCR5 activation is mediated
by Gaq [40]. In the U87 astrocyte cell line, calcium release induced
by Gaq-mediated activation of PLC was required for successful
infection [68], suggesting that a dopamine-mediated increase in
calcium may increase HIV entry.
The primary pathway by which DR mediate increased calcium
release from the endoplasmic reticulum is a ‘‘potentiation’’
mechanism. In this mechanism, stimulation of a Gaq-coupled
receptor, such as CCR5, initiates calcium release and then calcium
flux is potentiated through a second pathway. Studies show that
D1R-induced Gas- and PKA-mediated activation of IP3R [69] or
D2R-induced PLC- and calcyon-mediated activation of IP3R [70]
can potentiate Gaq-mediated calcium release. Thus, it is possible
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that both D1-like and D2-like DR increase entry through calcium
release mediated by distinct pathways, as both of these mecha-
nisms were shown to be specific to one DR subtype. However, the
data show no additive or synergistic effect on entry resulting from
activation of both D1-like and D2-like DR, and if the two types of
DR were acting on distinct signaling pathways, the effects on entry
might be more than for either pathway alone as both pathways
acted to increase entry. This suggests that the DR induced effects
on HIV entry may be mediated by a common signaling pathway.
One possible common mechanism for mediating calcium
release through activation of both D1-like and D2-like DR is
Gbc subunit-mediated PLCb activation [127], which could be
initiated by both subtypes of DR. Using our transfected HEK293
cells, we demonstrated that both D1R and D2R potentiate
calcium mobilization initiated by Gaq activation, and that these
effects were specifically mediated by activation of PLC. Thus,
activation of either D1-like or D2-like DR could potentiate the
Gaq-mediated calcium flux initiated by gp120-CCR5 binding, and
the resulting increase in calcium could increase HIV entry.
Although this mechanism addresses the involvement of both
dopamine receptor subtypes and CCR5 in the increase in HIV
entry, DR signaling in primary human macrophages is poorly
defined and entry could also be increased by a separate effect of
DR activation. For example, DR have been reported to form
oligomers with other GPCRs that alter receptor pharmacology,
trafficking and signaling [128–132]. If DR-CCR5 heteromers
were formed, this could alter the conformation or trafficking of
CCR5 to enhance its ability to bind viral particles or increase the
efficiency of the membrane fusion process. Thus, there are several
possible mechanisms by which these receptors could mediate the
increase in HIV entry. Regardless of these possibilities, our data
demonstrate that dopamine alters a stage of the replication cycle
between viral attachment and uncoating, the beginning and end of
the entry process, respectively [133]. Studies are ongoing
examining dopaminergic changes in the expression and function
of host and viral proteins involved in the entry process.
Dopamine-mediated increases in HIV infection of macrophages
could have a substantial impact on early HIV infection in the
CNS, where most viruses are R5-tropic [112]. During acute
infection, before most individuals know they are infected and/or
begin therapy, infection of a greater number of CNS macrophages
could increase the amount of HIV in the CNS, accelerating both
the spread of infection and the developing neuroinflammation
present early after CNS invasion [134,135]. This possibility is
supported by a recent study showing that methamphetamine is
associated with increased neurocognitive impairment in early stage
HIV infection [136]. A high percentage of HIV-positive individ-
uals are drug users [137–140] and often have poor adherence to
medication [141–145]. Therefore, an increase in viral entry into
macrophages could also be significant during the course of
infection with each subsequent use of a drug during a medication
hiatus.
The adverse effects of dopamine on HIV replication are not
limited to HIV-infected drug abusers but could also impact
individuals prescribed legal therapeutics that alter dopamine
levels. These drugs include L-DOPA or direct acting DR agonists
for Parkinson’s disease [146], Ritalin [24], and antidepressants and
psychiatric drugs such as Bupropion, a norepinephrine-dopamine
reuptake inhibitor [23] or Abilify, a partial D2-like DR agonist
[147]. There is a high prevalence of psychiatric disorders among
HIV infected people [148–152]. These individuals are more likely
to be prescribed drugs that modulate the dopaminergic system and
thereby might increase the progression of HIV infection in the
CNS.
In addition to drug-induced increases in dopamine, numerous
studies have found that HIV infection by itself can alter the CNS
dopaminergic system. Some studies show dopamine and dopa-
mine metabolites are reduced in postmortem brains from HIV
infected individuals [153–155] and in the CSF of HIV+
individuals with late stage disease [156–159]. However, another
study showed increased CNS dopamine in the CSF of therapy-
naive, HIV-infected people in early stage disease [160,161].
Postmortem data from individuals with HIV encephalitis also
suggested increased dopaminergic tone in the striatum [162].
Additionally, some studies show CNS hypermetabolism in
subcortical regions such as the basal ganglia in earlier stages of
infection, and subcortical hypometabolism in later stage disease
[163–166]. Thus, HIV infection may have different effects on
CNS metabolism at different stages of disease, and may potentially
increase CNS dopamine in subcortical structures in early stage
disease before reducing CNS dopamine during more advanced
infection. A study examining changes in cerebral metabolism in
drug abusers showed that intravenous drug use may have a
synergistic effect with HIV on cerebral metabolism, increasing
subcortical hypermetabolism and inducing the premature emer-
gence of cortical hypometabolism relative to HIV infected non-
drug users [166]. Thus, use of drugs of abuse or other substances
that increase CNS dopamine during early stage infection could
increase the already elevated levels of dopamine that may occur in
early HIV infection of the CNS, increasing the number of
macrophages exposed to higher levels of dopamine. Conversely, in
late stage disease, HIV+ individuals may be less susceptible to a
dopamine-mediated increase in macrophage infection due to the
lower dopaminergic tone in the CNS.
The data in this study show that the number of macrophages
infected with HIV is greater in the presence of increased
dopamine. Elevated dopamine may significantly impact the onset
and initial progression of HIV CNS infection by enabling the virus
to enter more macrophages early in infection. This would increase
the amount of virus in the CNS, contributing to the development
of inflammation and the formation of viral reservoirs. Thus,
increases in CNS dopamine may be a common mechanism by
which different drugs of abuse modulate the development of
HAND. Overall, these data contribute to our understanding of
HIV infection of the CNS and the development of HAND in
HIV-infected drug abusers and may help to guide the use of
therapeutic interventions in HIV-infected drug abusers.
Acknowledgments
We would like to thank all of the members of Dr. Joan W. Berman’s
laboratory at Einstein, especially Dr. Tina Calderon, for important
discussions, and Dr. Jennifer Cano Granit, a former student in the Kalpana
Laboratory, for help with the optimization of the entry assay. We would
also like to thank the Flow Cytometry Facility, especially Lydia Tesfa, and
the Einstein Center For AIDS Research (AI-051519) for their assistance,
especially Xuhong Wu and the CFAR Virology Core, for invaluable
assistance generating the viral stocks and developing the entry assay.
Author Contributions
Conceived and designed the experiments: PJG HHY GVK JAJ JWB.
Performed the experiments: PJG HHY. Analyzed the data: PJG HHY JAJ
JWB. Contributed reagents/hs/analysis tools: PJG GVK JAJ JWB.
Contributed to the writing of the manuscript: PJG HHY GVK JAJ
JWB. Edited the manuscript: PJG HHY GVK JAJ JWB.
Dopamine Increases HIV Entry into Macrophages
PLOS ONE | www.plosone.org 10 September 2014 | Volume 9 | Issue 9 | e108232
References
1. Valcour V, Chalermchai T, Sailasuta N, Marovich M, Lerdlum S, et al. (2012)
Central Nervous System Viral Invasion and Inflammation During Acute HIV
Infection. J Infect Dis 206: 275–282.
2. Cysique LA, Maruff P, Brew BJ (2004) Prevalence and pattern of
neuropsychological impairment in human immunodeficiency virus-infected/
acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and
post-highly active antiretroviral therapy eras: a combined study of two cohorts.
J Neurovirol 10: 350–357.
3. Heaton RK, Clifford DB, Franklin DR, Jr., Woods SP, Ake C, et al. (2010)
HIV-associated neurocognitive disorders persist in the era of potent
antiretroviral therapy: CHARTER Study. Neurology 75: 2087–2096.
4. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, et al. (2011)
HIV-associated neurocognitive disorders before and during the era of
combination antiretroviral therapy: differences in rates, nature, and predictors.
J Neurovirol 17: 3–16.
5. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, et al.
(2010) Cognitive dysfunction in HIV patients despite long-standing suppression
of viremia. AIDS 24: 1243–1250.
6. Tozzi V, Balestra P, Serraino D, Bellagamba R, Corpolongo A, et al. (2005)
Neurocognitive impairment and survival in a cohort of HIV-infected patients
treated with HAART. AIDS Res Hum Retroviruses 21: 706–713.
7. Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH,
et al. (1986) Detection of AIDS virus in macrophages in brain tissue from AIDS
patients with encephalopathy. Science 233: 1089–1093.
8. Takahashi K, Wesselingh SL, Griffin DE, McArthur JC, Johnson RT, et al.
(1996) Localization of HIV-1 in human brain using polymerase chain reaction/
in situ hybridization and immunocytochemistry. Ann Neurol 39: 705–711.
9. Williams KC, Corey S, Westmoreland SV, Pauley D, Knight H, et al. (2001)
Perivascular macrophages are the primary cell type productively infected by
simian immunodeficiency virus in the brains of macaques: implications for the
neuropathogenesis of AIDS. J Exp Med 193: 905–915.
10. Williams DW, Veenstra M, Gaskill PJ, Morgello S, Calderon TM, et al. (2014)
Monocytes Mediate HIV Neuropathogenesis: Mechanisms that Contribute to
HIV Associated Neurocognitive Disorders. Curr HIV Res.
11. Eugenin EA, Berman JW (2007) Gap junctions mediate human immunode-
ficiency virus-bystander killing in astrocytes. J Neurosci 27: 12844–12850.
12. Churchill MJ, Wesselingh SL, Cowley D, Pardo CA, McArthur JC, et al. (2009)
Extensive astrocyte infection is prominent in human immunodeficiency virus-
associated dementia. Ann Neurol 66: 253–258.
13. Koppensteiner H, Brack-Werner R, Schindler M (2012) Macrophages and
their relevance in Human Immunodeficiency Virus Type I infection.
Retrovirology 9: 82.
14. Yadav A, Collman RG (2009) CNS inflammation and macrophage/microglial
biology associated with HIV-1 infection. J Neuroimmune Pharmacol 4: 430–
447.
15. Hult B, Chana G, Masliah E, Everall I (2008) Neurobiology of HIV. Int Rev
Psychiatry 20: 3–13.
16. Williams KC, Hickey WF (2002) Central nervous system damage, monocytes
and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci 25:
537–562.
17. Churchill M, Nath A (2013) Where does HIV hide? A focus on the central
nervous system. Curr Opin HIV AIDS 8: 165–169.
18. Thompson KA, Cherry CL, Bell JE, McLean CA (2011) Brain cell reservoirs of
latent virus in presymptomatic HIV-infected individuals. Am J Pathol 179:
1623–1629.
19. Brabers NA, Nottet HS (2006) Role of the pro-inflammatory cytokines TNF-
alpha and IL-1beta in HIV-associated dementia. Eur J Clin Invest 36: 447–
458.
20. Kraft-Terry SD, Buch SJ, Fox HS, Gendelman HE (2009) A coat of many
colors: neuroimmune crosstalk in human immunodeficiency virus infection.
Neuron 64: 133–145.
21. Carboni E, Imperato A, Perezzani L, Di Chiara G (1989) Amphetamine,
cocaine, phencyclidine and nomifensine increase extracellular dopamine
concentrations preferentially in the nucleus accumbens of freely moving rats.
Neuroscience 28: 653–661.
22. Olive MF, Taylor Lewis (2013) The neurocircuitry of illicit psychostimulant
addiction: acute and chronic effects in humans. Substance Abuse and
Rehabilitation: 29.
23. Papakostas GI (2006) Dopaminergic-based pharmacotherapies for depression.
Eur Neuropsychopharmacol 16: 391–402.
24. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, et al. (2001)
Therapeutic doses of oral methylphenidate significantly increase extracellular
dopamine in the human brain. J Neurosci 21: RC121.
25. Czub S, Koutsilieri E, Sopper S, Czub M, Stahl-Hennig C, et al. (2001)
Enhancement of central nervous system pathology in early simian immuno-
deficiency virus infection by dopaminergic drugs. Acta Neuropathol 101: 85–
91.
26. Czub S, Czub M, Koutsilieri E, Sopper S, Villinger F, et al. (2004) Modulation
of simian immunodeficiency virus neuropathology by dopaminergic drugs.
Acta Neuropathol 107: 216–226.
27. Aylward EH, Brettschneider PD, McArthur JC, Harris GJ, Schlaepfer TE, et
al. (1995) Magnetic resonance imaging measurement of gray matter volume
reductions in HIV dementia. Am J Psychiatry 152: 987–994.
28. Aylward EH, Henderer JD, McArthur JC, Brettschneider PD, Harris GJ, et al.
(1993) Reduced basal ganglia volume in HIV-1-associated dementia: results
from quantitative neuroimaging. Neurology 43: 2099–2104.
29. Navia BA, Jordan BD, Price RW (1986) The AIDS dementia complex: I.
Clinical features. Ann Neurol 19: 517–524.
30. Reyes MG, Faraldi F, Senseng CS, Flowers C, Fariello R (1991) Nigral
degeneration in acquired immune deficiency syndrome (AIDS). Acta
Neuropathol 82: 39–44.
31. Berger JR, Arendt G (2000) HIV dementia: the role of the basal ganglia and
dopaminergic systems. J Psychopharmacol 14: 214–221.
32. Purohit V, Rapaka R, Shurtleff D (2011) Drugs of abuse, dopamine, and HIV-
associated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol
44: 102–110.
33. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine
receptors: from structure to function. Physiol Rev 78: 189–225.
34. Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and
pharmacology of dopamine receptors. Pharmacol Rev 63: 182–217.
35. Chun LS, Free RB, Doyle TB, Huang XP, Rankin ML, et al. (2013) D1-D2
dopamine receptor synergy promotes calcium signaling via multiple mecha-
nisms. Mol Pharmacol 84: 190–200.
36. Hasbi A, Fan T, Alijaniaram M, Nguyen T, Perreault ML, et al. (2009)
Calcium signaling cascade links dopamine D1-D2 receptor heteromer to
striatal BDNF production and neuronal growth. Proc Natl Acad Sci U S A
106: 21377–21382.
37. Rashid AJ, So CH, Kong MM, Furtak T, El-Ghundi M, et al. (2007) D1-D2
dopamine receptor heterooligomers with unique pharmacology are coupled to
rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci U S A 104: 654–
659.
38. Gaskill PJ, Calderon TM, Luers AJ, Eugenin EA, Javitch JA, et al. (2009)
Human immunodeficiency virus (HIV) infection of human macrophages is
increased by dopamine: a bridge between HIV-associated neurologic disorders
and drug abuse. Am J Pathol 175: 1148–1159.
39. Berger EA, Murphy PM, Farber JM (1999) Chemokine receptors as HIV-1
coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17:
657–700.
40. Arai H, Charo IF (1996) Differential regulation of G-protein-mediated
signaling by chemokine receptors. J Biol Chem 271: 21814–21819.
41. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, et al. (1999) A
small-molecule, nonpeptide CCR5 antagonist with highly potent and selective
anti-HIV-1 activity. Proc Natl Acad Sci U S A 96: 5698–5703.
42. Tobiume M, Lineberger JE, Lundquist CA, Miller MD, Aiken C (2003) Nef
does not affect the efficiency of human immunodeficiency virus type 1 fusion
with target cells. J Virol 77: 10645–10650.
43. Morner A, Bjorndal A, Albert J, Kewalramani VN, Littman DR, et al. (1999)
Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1
isolates, frequently use CCR5 but show promiscuity in coreceptor usage.
J Virol 73: 2343–2349.
44. Hazleton JE, Berman JW, Eugenin EA (2012) Purinergic receptors are required
for HIV-1 infection of primary human macrophages. J Immunol 188: 4488–
4495.
45. Cavrois M, De Noronha C, Greene WC (2002) A sensitive and specific
enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes.
Nat Biotechnol 20: 1151–1154.
46. Li W, Yu M, Bai L, Bu D, Xu X (2006) Downregulation of CCR5 expression
on cells by recombinant adenovirus containing antisense CCR5, a possible
measure to prevent HIV-1 from entering target cells. J Acquir Immune Defic
Syndr 43: 516–522.
47. Naif HM, Li S, Ho-Shon M, Mathijs JM, Williamson P, et al. (1997) The state
of maturation of monocytes into macrophages determines the effects of IL-4
and IL-13 on HIV replication. J Immunol 158: 501–511.
48. Tuttle DL, Harrison JK, Anders C, Sleasman JW, Goodenow MM (1998)
Expression of CCR5 increases during monocyte differentiation and directly
mediates macrophage susceptibility to infection by human immunodeficiency
virus type 1. J Virol 72: 4962–4969.
49. Wang J, Crawford K, Yuan M, Wang H, Gorry PR, et al. (2002) Regulation of
CC chemokine receptor 5 and CD4 expression and human immunodeficiency
virus type 1 replication in human macrophages and microglia by T helper type
2 cytokines. J Infect Dis 185: 885–897.
50. Sozzani S, Ghezzi S, Iannolo G, Luini W, Borsatti A, et al. (1998) Interleukin
10 increases CCR5 expression and HIV infection in human monocytes. J Exp
Med 187: 439–444.
51. Sartori E, Calistri A, Salata C, Del Vecchio C, Palu G, et al. (2011) Herpes
simplex virus type 2 infection increases human immunodeficiency virus type 1
entry into human primary macrophages. Virol J 8: 166.
52. Gabuzda D, Wang J (1999) Chemokine receptors and virus entry in the central
nervous system. J Neurovirol 5: 643–658.
53. Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, et al. (2004)
Biological analysis of human immunodeficiency virus type 1 R5 envelopes
Dopamine Increases HIV Entry into Macrophages
PLOS ONE | www.plosone.org 11 September 2014 | Volume 9 | Issue 9 | e108232
amplified from brain and lymph node tissues of AIDS patients with
neuropathology reveals two distinct tropism phenotypes and identifies
envelopes in the brain that confer an enhanced tropism and fusigenicity for
macrophages. J Virol 78: 6915–6926.
54. Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R (2011) HIV-1
replication in the central nervous system occurs in two distinct cell types. PLoS
Pathog 7: e1002286.
55. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, et al. (1996) The beta-
chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1
isolates. Cell 85: 1135–1148.
56. Jiang C, Parrish NF, Wilen CB, Li H, Chen Y, et al. (2011) Primary infection
by a human immunodeficiency virus with atypical coreceptor tropism. J Virol
85: 10669–10681.
57. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB (2009) HIV
enters cells via endocytosis and dynamin-dependent fusion with endosomes.
Cell 137: 433–444.
58. Rana S, Besson G, Cook DG, Rucker J, Smyth RJ, et al. (1997) Role of CCR5
in infection of primary macrophages and lymphocytes by macrophage-tropic
strains of human immunodeficiency virus: resistance to patient-derived and
prototype isolates resulting from the delta ccr5 mutation. J Virol 71: 3219–
3227.
59. Verani A, Pesenti E, Polo S, Tresoldi E, Scarlatti G, et al. (1998) CXCR4 is a
functional coreceptor for infection of human macrophages by CXCR4-
dependent primary HIV-1 isolates. J Immunol 161: 2084–2088.
60. Gorry PR, Bristol G, Zack JA, Ritola K, Swanstrom R, et al. (2001)
Macrophage tropism of human immunodeficiency virus type 1 isolates from
brain and lymphoid tissues predicts neurotropism independent of coreceptor
specificity. J Virol 75: 10073–10089.
61. Hasko G, Szabo C, Nemeth ZH, Deitch EA (2002) Dopamine suppresses IL-12
p40 production by lipopolysaccharide-stimulated macrophages via a beta-
adrenoceptor-mediated mechanism. J Neuroimmunol 122: 34–39.
62. Lin Y, Quartermain D, Dunn AJ, Weinshenker D, Stone EA (2008) Possible
dopaminergic stimulation of locus coeruleus alpha1-adrenoceptors involved in
behavioral activation. Synapse 62: 516–523.
63. Seeman P, Corbett R, Van Tol HH (1998) Dopamine D4 receptors may
alleviate antipsychotic-induced parkinsonism. Adv Pharmacol 42: 478–482.
64. Sunahara RK, Guan HC, O’Dowd BF, Seeman P, Laurier LG, et al. (1991)
Cloning of the gene for a human dopamine D5 receptor with higher affinity for
dopamine than D1. Nature 350: 614–619.
65. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, et al. (1998)
Standard binding and functional assays related to medications development
division testing for potential cocaine and opiate narcotic treatment medications.
NIDA Res Monogr 178: 440–466.
66. Arthos J, Rubbert A, Rabin RL, Cicala C, Machado E, et al. (2000) CCR5
signal transduction in macrophages by human immunodeficiency virus and
simian immunodeficiency virus envelopes. J Virol 74: 6418–6424.
67. Lee C, Liu QH, Tomkowicz B, Yi Y, Freedman BD, et al. (2003) Macrophage
activation through CCR5- and CXCR4-mediated gp120-elicited signaling
pathways. J Leukoc Biol 74: 676–682.
68. Harmon B, Ratner L (2008) Induction of the G q Signaling Cascade by the
Human Immunodeficiency Virus Envelope Is Required for Virus Entry.
Journal of Virology 82: 9191–9205.
69. Dai R, Ali MK, Lezcano N, Bergson C (2008) A crucial role for cAMP and
protein kinase A in D1 dopamine receptor regulated intracellular calcium
transients. Neurosignals 16: 112–123.
70. Fregeau MO, Carrier M, Guillemette G (2013) Mechanism of dopamine D2
receptor-induced Ca(2+) release in PC-12 cells. Cell Signal 25: 2871–2877.
71. Atwood BK, Lopez J, Wager-Miller J, Mackie K, Straiker A (2011) Expression
of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2,
and N18 cell lines as revealed by microarray analysis. BMC Genomics 12: 14.
72. Berridge MJ, Irvine RF (1989) Inositol phosphates and cell signalling. Nature
341: 197–205.
73. Bleasdale JE, Thakur NR, Gremban RS, Bundy GL, Fitzpatrick FA, et al.
(1990) Selective inhibition of receptor-coupled phospholipase C-dependent
processes in human platelets and polymorphonuclear neutrophils. J Pharmacol
Exp Ther 255: 756–768.
74. Fujimura RK, Goodkin K, Petito CK, Douyon R, Feaster DJ, et al. (1997)
HIV-1 proviral DNA load across neuroanatomic regions of individuals with
evidence for HIV-1-associated dementia. J Acquir Immune Defic Syndr Hum
Retrovirol 16: 146–152.
75. Itoh K, Mehraein P, Weis S (2000) Neuronal damage of the substantia nigra in
HIV-1 infected brains. Acta Neuropathol 99: 376–384.
76. Marcondes MC, Flynn C, Watry DD, Zandonatti M, Fox HS (2010)
Methamphetamine increases brain viral load and activates natural killer cells
in simian immunodeficiency virus-infected monkeys. Am J Pathol 177: 355–
361.
77. Gaskill PJ, Carvallo L, Eugenin EA, Berman JW (2012) Characterization and
function of the human macrophage dopaminergic system: implications for CNS
disease and drug abuse. J Neuroinflammation 9: 203.
78. Gaskill PJ, Calderon TM, Coley JS, Berman JW (2013) Drug Induced Increases
in CNS Dopamine Alter Monocyte, Macrophage and T Cell Functions:
Implications for HAND. J Neuroimmune Pharmacol.
79. Wightman RM, Robinson DL (2002) Transient changes in mesolimbic
dopamine and their association with ‘reward’. J Neurochem 82: 721–735.
80. Garris PA, Ciolkowski EL, Pastore P, Wightman RM (1994) Efflux of
dopamine from the synaptic cleft in the nucleus accumbens of the rat brain.
J Neurosci 14: 6084–6093.
81. Garris PA, Wightman RM (1994) In vivo voltammetric measurement of evoked
extracellular dopamine in the rat basolateral amygdaloid nucleus. J Physiol 478
( Pt 2): 239–249.
82. Spuhler IA, Hauri A (2013) Decoding the dopamine signal in macaque
prefrontal cortex: a simulation study using the Cx3Dp simulator. PLoS One 8:
e71615.
83. Wightman PAGRM (1995) Voltammetric Methods in Brain Systems.
Neuromethods. Totowa, New Jersey: Humana Press. 349.
84. Girault JA, Greengard P (2004) The neurobiology of dopamine signaling. Arch
Neurol 61: 641–644.
85. Venton BJ, Zhang H, Garris PA, Phillips PEM, Sulzer D, et al. (2003) Real-
time decoding of dopamine concentration changes in the caudate-putamen
during tonic and phasic firing. Journal of Neurochemistry 87: 1284–1295.
86. Ford CP, Gantz SC, Phillips PE, Williams JT (2010) Control of extracellular
dopamine at dendrite and axon terminals. J Neurosci 30: 6975–6983.
87. Rice ME, Patel JC, Cragg SJ (2011) Dopamine release in the basal ganglia.
Neuroscience 198: 112–137.
88. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially
increase synaptic dopamine concentrations in the mesolimbic system of freely
moving rats. Proc Natl Acad Sci U S A 85: 5274–5278.
89. Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of
reward pathways. Trends Pharmacol Sci 13: 177–184.
90. Urban NB, Kegeles LS, Slifstein M, Xu X, Martinez D, et al. (2010) Sex
differences in striatal dopamine release in young adults after oral alcohol
challenge: a positron emission tomography imaging study with [(1)(1)C]raclo-
pride. Biol Psychiatry 68: 689–696.
91. Urban NB, Slifstein M, Thompson JL, Xu X, Girgis RR, et al. (2012)
Dopamine release in chronic cannabis users: a [11c]raclopride positron
emission tomography study. Biol Psychiatry 71: 677–683.
92. Xi ZX, Kleitz HK, Deng X, Ladenheim B, Peng XQ, et al. (2009) A single
high dose of methamphetamine increases cocaine self-administration by
depletion of striatal dopamine in rats. Neuroscience 161: 392–402.
93. Zachek MK, Takmakov P, Park J, Wightman RM, McCarty GS (2010)
Simultaneous monitoring of dopamine concentration at spatially different brain
locations in vivo. Biosens Bioelectron 25: 1179–1185.
94. Luscher C, Malenka RC (2011) Drug-evoked synaptic plasticity in addiction:
from molecular changes to circuit remodeling. Neuron 69: 650–663.
95. Sulzer D (2011) How addictive drugs disrupt presynaptic dopamine
neurotransmission. Neuron 69: 628–649.
96. Volkow ND, Wang GJ, Fowler JS, Tomasi D (2012) Addiction circuitry in the
human brain. Annu Rev Pharmacol Toxicol 52: 321–336.
97. Cragg SJ, Nicholson C, Kume-Kick J, Tao L, Rice ME (2001) Dopamine-
mediated volume transmission in midbrain is regulated by distinct extracellular
geometry and uptake. J Neurophysiol 85: 1761–1771.
98. Fuxe K, Borroto-Escuela DO, Romero-Fernandez W, Zhang WB, Agnati LF
(2013) Volume transmission and its different forms in the central nervous
system. Chin J Integr Med 19: 323–329.
99. Lee T, Cai LX, Lelyveld VS, Hai A, Jasanoff A (2014) Molecular-level
functional magnetic resonance imaging of dopaminergic signaling. Science 344:
533–535.
100. Stamford JA, Kruk ZL, Palij P, Millar J (1988) Diffusion and uptake of
dopamine in rat caudate and nucleus accumbens compared using fast cyclic
voltammetry. Brain Res 448: 381–385.
101. Cragg SJ, Rice ME (2004) DAncing past the DAT at a DA synapse. Trends
Neurosci 27: 270–277.
102. Rice ME, Cragg SJ (2008) Dopamine spillover after quantal release: rethinking
dopamine transmission in the nigrostriatal pathway. Brain Res Rev 58: 303–
313.
103. Vizi ES, Fekete A, Karoly R, Mike A (2010) Non-synaptic receptors and
transporters involved in brain functions and targets of drug treatment.
Br J Pharmacol 160: 785–809.
104. Trueta C, De-Miguel FF (2012) Extrasynaptic exocytosis and its mechanisms: a
source of molecules mediating volume transmission in the nervous system.
Front Physiol 3: 319.
105. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F (2011) Addiction:
beyond dopamine reward circuitry. Proc Natl Acad Sci U S A 108: 15037–
15042.
106. Abi-Dargham A, Kegeles LS, Martinez D, Innis RB, Laruelle M (2003)
Dopamine mediation of positive reinforcing effects of amphetamine in
stimulant naı&#x0308;ve healthy volunteers: results from a large cohort.
European Neuropsychopharmacology 13: 459–468.
107. Volkow ND, Wang GJ, Tomasi D, Kollins SH, Wigal TL, et al. (2012)
Methylphenidate-elicited dopamine increases in ventral striatum are associated
with long-term symptom improvement in adults with attention deficit
hyperactivity disorder. J Neurosci 32: 841–849.
108. Zhang L, Dong Y, Doyon WM, Dani JA (2012) Withdrawal from chronic
nicotine exposure alters dopamine signaling dynamics in the nucleus
accumbens. Biol Psychiatry 71: 184–191.
109. Grace AA (1995) The tonic/phasic model of dopamine system regulation: its
relevance for understanding how stimulant abuse can alter basal ganglia
function. Drug Alcohol Depend 37: 111–129.
Dopamine Increases HIV Entry into Macrophages
PLOS ONE | www.plosone.org 12 September 2014 | Volume 9 | Issue 9 | e108232
110. Martinez D, Narendran R, Foltin RW, Slifstein M, Hwang DR, et al. (2007)
Amphetamine-induced dopamine release: markedly blunted in cocaine
dependence and predictive of the choice to self-administer cocaine.
Am J Psychiatry 164: 622–629.
111. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, et al. (1997) Decreased
striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects.
Nature 386: 830–833.
112. Gabuzda D, Wang J (2000) Chemokine receptors and mechanisms of cell death
in HIV neuropathogenesis. J Neurovirol 6 Suppl 1: S24–32.
113. Gorry PR, Taylor J, Holm GH, Mehle A, Morgan T, et al. (2002) Increased
CCR5 Affinity and Reduced CCR5/CD4 Dependence of a Neurovirulent
Primary Human Immunodeficiency Virus Type 1 Isolate. Journal of Virology
76: 6277–6292.
114. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D (1998) Effects of
CCR5 and CD4 cell surface concentrations on infections by macrophagetropic
isolates of human immunodeficiency virus type 1. J Virol 72: 2855–2864.
115. Martin-Garcia J, Cao W, Varela-Rohena A, Plassmeyer ML, Gonzalez-
Scarano F (2006) HIV-1 tropism for the central nervous system: Brain-derived
envelope glycoproteins with lower CD4 dependence and reduced sensitivity to
a fusion inhibitor. Virology 346: 169–179.
116. Lewin SR, Sonza S, Irving LB, McDonald CF, Mills J, et al. (1996) Surface
CD4 is critical to in vitro HIV infection of human alveolar macrophages. AIDS
Res Hum Retroviruses 12: 877–883.
117. Dick AD, Pell M, Brew BJ, Foulcher E, Sedgwick JD (1997) Direct ex vivo flow
cytometric analysis of human microglial cell CD4 expression: examination of
central nervous system biopsy specimens from HIV-seropositive patients and
patients with other neurological disease. AIDS 11: 1699–1708.
118. Blanpain C, Vanderwinden JM, Cihak J, Wittamer V, Le Poul E, et al. (2002)
Multiple active states and oligomerization of CCR5 revealed by functional
properties of monoclonal antibodies. Mol Biol Cell 13: 723–737.
119. de Voux A, Chan MC, Folefoc AT, Madziva MT, Flanagan CA (2013)
Constitutively active CCR5 chemokine receptors differ in mediating HIV
envelope-dependent fusion. PLoS One 8: e54532.
120. Salimi H, Roche M, Webb N, Gray LR, Chikere K, et al. (2012) Macrophage-
tropic HIV-1 variants from brain demonstrate alterations in the way gp120
engages both CD4 and CCR5. J Leukoc Biol.
121. Flanagan CA (2014) Receptor Conformation and Constitutive Activity in
CCR5 Chemokine Receptor Function and HIV Infection. Adv Pharmacol 70:
215–263.
122. Gendelman HE, Orenstein JM, Martin MA, Ferrua C, Mitra R, et al. (1988)
Efficient isolation and propagation of human immunodeficiency virus on
recombinant colony-stimulating factor 1-treated monocytes. J Exp Med 167:
1428–1441.
123. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, et al. (1991) Molecular
characterization of human immunodeficiency virus type 1 cloned directly from
uncultured human brain tissue: identification of replication-competent and -
defective viral genomes. J Virol 65: 3973–3985.
124. Hasbi A, O’Dowd BF, George SR (2011) Dopamine D1-D2 receptor
heteromer signaling pathway in the brain: emerging physiological relevance.
Mol Brain 4: 26.
125. Melar M, Ott DE, Hope TJ (2007) Physiological levels of virion-associated
human immunodeficiency virus type 1 envelope induce coreceptor-dependent
calcium flux. J Virol 81: 1773–1785.
126. Liu QH, Williams DA, McManus C, Baribaud F, Doms RW, et al. (2000)
HIV-1 gp120 and chemokines activate ion channels in primary macrophages
through CCR5 and CXCR4 stimulation. Proc Natl Acad Sci U S A 97: 4832–
4837.
127. Stehno-Bittel L, Krapivinsky G, Krapivinsky L, Perez-Terzic C, Clapham DE
(1995) The G protein beta gamma subunit transduces the muscarinic receptor
signal for Ca2+ release in Xenopus oocytes. J Biol Chem 270: 30068–30074.
128. Bonaventura J, Rico AJ, Moreno E, Sierra S, Sanchez M, et al. (2014) l-DOPA-
treatment in primates disrupts the expression of A2A adenosine-CB1
cannabinoid-D2 dopamine receptor heteromers in the caudate nucleus.
Neuropharmacology 79: 90–100.
129. Han Y, Moreira IS, Urizar E, Weinstein H, Javitch JA (2009) Allosteric
communication between protomers of dopamine class A GPCR dimers
modulates activation. Nat Chem Biol 5: 688–695.
130. Guo W, Urizar E, Kralikova M, Mobarec JC, Shi L, et al. (2008) Dopamine
D2 receptors form higher order oligomers at physiological expression levels.
EMBO J 27: 2293–2304.
131. Fuxe K, Canals M, Torvinen M, Marcellino D, Terasmaa A, et al. (2007)
Intramembrane receptor-receptor interactions: a novel principle in molecular
medicine. J Neural Transm 114: 49–75.
132. Franco R, Lluis C, Canela EI, Mallol J, Agnati L, et al. (2007) Receptor-
receptor interactions involving adenosine A1 or dopamine D1 receptors and
accessory proteins. J Neural Transm 114: 93–104.
133. Arhel N (2010) Revisiting HIV-1 uncoating. Retrovirology 7: 96.
134. Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, et al. (2011) Central
nervous system immune activation characterizes primary human immunode-
ficiency virus 1 infection even in participants with minimal cerebrospinal fluid
viral burden. J Infect Dis 204: 753–760.
135. Gray F, Scaravilli F, Everall I, Chretien F, An S, et al. (1996) Neuropathology
of early HIV-1 infection. Brain Pathol 6: 1–15.
136. Weber E, Morgan EE, Iudicello JE, Blackstone K, Grant I, et al. (2013)
Substance use is a risk factor for neurocognitive deficits and neuropsychiatric
distress in acute and early HIV infection. J Neurovirol 19: 65–74.
137. Substance Abuse and Mental Health Services Administration CfBHSaQ (2010)
The NSDUH Report: HIV/AIDS and Substance Use. Rockville, MD.
138. Beyrer C, Wirtz AL, Baral S, Peryskina A, Sifakis F (2010) Epidemiologic links
between drug use and HIV epidemics: an international perspective. J Acquir
Immune Defic Syndr 55 Suppl 1: S10–16.
139. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, et al. (2008)
Global epidemiology of injecting drug use and HIV among people who inject
drugs: a systematic review. Lancet 372: 1733–1745.
140. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, et al.
(2001) Psychiatric disorders and drug use among human immunodeficiency
virus-infected adults in the United States. Arch Gen Psychiatry 58: 721–728.
141. Moore DJ, Blackstone K, Woods SP, Ellis RJ, Atkinson JH, et al. (2012)
Methamphetamine use and neuropsychiatric factors are associated with
antiretroviral non-adherence. AIDS Care 24: 1504–1513.
142. Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, et al. (2007)
Drug use and medication adherence among HIV-1 infected individuals. AIDS
Behav 11: 185–194.
143. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, et al.
(2002) Impact of active drug use on antiretroviral therapy adherence and viral
suppression in HIV-infected drug users. J Gen Intern Med 17: 377–381.
144. Berg KM, Wilson IB, Li X, Arnsten JH (2012) Comparison of antiretroviral
adherence questions. AIDS Behav 16: 461–468.
145. Rosen MI, Black AC, Arnsten JH, Goggin K, Remien RH, et al. (2013)
Association between use of specific drugs and antiretroviral adherence: findings
from MACH 14. AIDS Behav 17: 142–147.
146. Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, et al. (2011)
Priorities in Parkinson’s disease research. Nat Rev Drug Discov 10: 377–393.
147. Burris KD (2002) Aripiprazole, a Novel Antipsychotic, Is a High-Affinity
Partial Agonist at Human Dopamine D2 Receptors. Journal of Pharmacology
and Experimental Therapeutics 302: 381–389.
148. Rosenberg SD, Goodman LA, Osher FC, Swartz MS, Essock SM, et al. (2001)
Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental
illness. Am J Public Health 91: 31–37.
149. Himelhoch S, McCarthy JF, Ganoczy D, Medoff D, Dixon LB, et al. (2007)
Understanding associations between serious mental illness and HIV among
patients in the VA Health System. Psychiatr Serv 58: 1165–1172.
150. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, et al. (2011)
HIV-associated neurocognitive disorders before and during the era of
combination antiretroviral therapy: differences in rates, nature, and predictors.
J Neurovirol 17: 3–16.
151. Brown GR, Rundell JR, McManis SE, Kendall SN, Zachary R, et al. (1992)
Prevalence of psychiatric disorders in early stages of HIV infection. Psychosom
Med 54: 588–601.
152. Blank MB, Mandell DS, Aiken L, Hadley TR (2002) Co-occurrence of HIV
and serious mental illness among Medicaid recipients. Psychiatr Serv 53: 868–
873.
153. Sardar AM, Czudek C, Reynolds GP (1996) Dopamine deficits in the brain: the
neurochemical basis of parkinsonian symptoms in AIDS. Neuroreport 7: 910–
912.
154. Kumar AM, Fernandez JB, Singer EJ, Commins D, Waldrop-Valverde D, et
al. (2009) Human immunodeficiency virus type 1 in the central nervous system
leads to decreased dopamine in different regions of postmortem human brains.
J Neurovirol 15: 257–274.
155. Kumar AM, Ownby RL, Waldrop-Valverde D, Fernandez B, Kumar M (2011)
Human immunodeficiency virus infection in the CNS and decreased dopamine
availability: relationship with neuropsychological performance. J Neurovirol
17: 26–40.
156. Larsson M, Hagberg L, Forsman A, Norkrans G (1991) Cerebrospinal fluid
catecholamine metabolites in HIV-infected patients. J Neurosci Res 28: 406–
409.
157. Berger JR, Kumar M, Kumar A, Fernandez JB, Levin B (1994) Cerebrospinal
fluid dopamine in HIV-1 infection. AIDS 8: 67–71.
158. di Rocco A, Bottiglieri T, Dorfman D, Werner P, Morrison C, et al. (2000)
Decreased homovanilic acid in cerebrospinal fluid correlates with impaired
neuropsychologic function in HIV-1-infected patients. Clin Neuropharmacol
23: 190–194.
159. Koutsilieri E, ter Meulen V, Riederer P (2001) Neurotransmission in HIV
associated dementia: a short review. J Neural Transm 108: 767–775.
160. Scheller C, Arendt G, Nolting T, Antke C, Sopper S, et al. (2010) Increased
dopaminergic neurotransmission in therapy-naive asymptomatic HIV patients
is not associated with adaptive changes at the dopaminergic synapses. J Neural
Transm 117: 699–705.
161. Horn A, Scheller C, du Plessis S, Arendt G, Nolting T, et al. (2013) Increases in
CSF dopamine in HIV patients are due to the dopamine transporter 10/10-
repeat allele which is more frequent in HIV-infected individuals. J Neural
Transm 120: 1411–1419.
162. Gelman BB, Spencer JA, Holzer CE, 3rd, Soukup VM (2006) Abnormal
striatal dopaminergic synapses in National NeuroAIDS Tissue Consortium
subjects with HIV encephalitis. J Neuroimmune Pharmacol 1: 410–420.
163. Rottenberg DA, Moeller JR, Strother SC, Sidtis JJ, Navia BA, et al. (1987) The
metabolic pathology of the AIDS dementia complex. Ann Neurol 22: 700–706.
Dopamine Increases HIV Entry into Macrophages
PLOS ONE | www.plosone.org 13 September 2014 | Volume 9 | Issue 9 | e108232
164. van Gorp WG, Mandelkern MA, Gee M, Hinkin CH, Stern CE, et al. (1992)
Cerebral metabolic dysfunction in AIDS: findings in a sample with and without
dementia. J Neuropsychiatry Clin Neurosci 4: 280–287.
165. Rottenberg DA, Sidtis JJ, Strother SC, Schaper KA, Anderson JR, et al. (1996)
Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and
without dementia. J Nucl Med 37: 1133–1141.
166. Georgiou MF, Gonenc A, Waldrop-Valverde D, Kuker RA, Ezuddin SH, et al.
(2008) Analysis of the effects of injecting drug use and HIV-1 infection on 18F-
FDG PET brain metabolism. J Nucl Med 49: 1999–2005.
Dopamine Increases HIV Entry into Macrophages
PLOS ONE | www.plosone.org 14 September 2014 | Volume 9 | Issue 9 | e108232
